Andrew Tutt
Led OlympiA, the trial that showed a year of olaparib after surgery improves survival in BRCA-mutated breast cancer.
Andrew Tutt's work on BRCA-deficient breast cancer, from the first PARP-inhibitor clinical proof-of-concept to the TNT trial of carboplatin and the OlympiA adjuvant olaparib trial, defined DNA-repair-targeted therapy in breast cancer.
Pages like this
not linked directly; found by shared links- PairingGermline BRCA test → adjuvant PARP inhibitor
Shares OlympiA, PARP inhibitors, Olaparib, BRCA1 / BRCA2 (HRD).
- PersonAlan Ashworth
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- PersonJohann de Bono
Shares The Institute of Cancer Research, The Royal Marsden, PARP inhibitors, Olaparib.
- PersonCharles E. Geyer Jr.
Shares OlympiA, OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, Olaparib, PARP.
- TrialPOLO
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- TrialSOLO-1
Shares PARP inhibitors, Olaparib, PARP, BRCA1 / BRCA2 (HRD).
- PairingPlatinum chemotherapy in HRD tumours
Shares Platinum agents, Carboplatin, BRCA1 / BRCA2 (HRD), Triple-negative breast cancer (TNBC).
- PersonSusan M. Domchek
Shares OlympiA: a year of olaparib after surgery for BRCA-mutated, high-risk early breast cancer, Olaparib, PARP, BRCA1 / BRCA2 (HRD).